Background--Monocrotaline has been widely used to establish an animal model of pulmonary hypertension. The molecular target underlying monocrotaline-induced pulmonary artery endothelial injury and pulmonary hypertension remains unknown. The extracellular calcium-sensing receptor (CaSR) and particularly its extracellular domain hold the potential structural basis for monocrotaline to bind. This study aimed to reveal whether monocrotaline induces pulmonary hypertension by targeting the CaSR.
M
onocrotaline was shown to induce pulmonary arteritis 1 and was used subsequently to establish an animal model of pulmonary hypertension by 1 subcutaneous or intraperitoneal injection. [2] [3] [4] Monocrotaline induces the selective damage of pulmonary artery endothelial cells (PAECs) and causes the development of pulmonary hypertension. [5] [6] [7] Increasing evidence highlights the potential role of the extracellular calcium-sensing receptor (CaSR) in the dysfunction of pulmonary vasculature. [8] [9] [10] The structure of CaSR, and particularly its extracellular domain, richly contains histidine, tryptophan, and cysteine and a specific motif of cysteine-X (noncysteine amino acid)-X-cysteine (CXXC), all of which offer the potential structural basis for monocrotaline to bind to a protein. [11] [12] [13] [14] This study aimed to examine the hypothesis that monocrotaline induces endothelial injury and pulmonary hypertension by binding and subsequent activating CaSR. Our studies used 3 different technological strategies including nuclear magnetic resonance (NMR) with purified CaSR protein, immunocytochemical staining of cultured PAECs, and cellular thermal shift assay on pulmonary arteries isolated from monocrotaline-administered rats, and all consistently demonstrated the binding of monocrotaline to CaSR. The evaluation of the downstream calcium signaling of CaSR indicated the activation of CaSR by monocrotaline and the subsequent damage of PAECs. Furthermore, our examination of a monocrotaline-administered rat model showed pulmonary hypertension to be significantly attenuated or almost completely abolished by the inhibitor of CaSR, global or lung tissue knockdown or knockout of CaSR. These findings finally and strongly demonstrated the mechanistic target of monocrotaline at CaSR.
Methods Ethics Approval
All studies using Sprague-Dawley rats were approved by the institutional animal care and use committee of Tongji Medical College, Huazhong University of Science and Technology, and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Fluorescein Isothiocyanate Labeling of Monocrotaline
Retronecine, the core structure of monocrotaline for its binding to protein 11, 15, 16 was exploited in the current study as the strategy for labeling monocrotaline with fluorescein isothiocyanate (FITC), as shown schematically in Figure 1 . The synthesis procedures consisted of 2 steps: the alkalization of monocrotaline to obtain retronecine 17 and then the ligation of FITC to retronecine. Briefly, potassium hydroxide (0.69 g) was added to monocrotaline (2 g) in MeOH (10 mL) at room temperature. The resulting solution was stirred at 100°C for 10 minutes, and then cooled to room temperature, and the solvent was removed under vacuum. The residue was purified on a silica gel (CHCl 3 :MeOH:NH 4 OH at 10:5:1) to afford retronecine as yellow oil (896 mg, 94.0%). Retronecine (0.65 g) was added to a solution of 5-FITC (1.79 g) in N,Ndimethylformamide (10 mL), the mixture was stirred at 30°C for 72 hours, and then dibutyltindilaurate (26.5 mg) was supplemented. The mixture was stirred at 50°C for an additional 24 hours, then quenched with EtOH (5 mL), and the solvent was removed under vacuum. The final mixture was purified on a C-18 flash column (MeOH in H 2 O: from 0% to 75% in 100 minutes) to afford the target compound, FITCconjugated monocrotaline (FITC-MCT; 167 mg). The compound was purified by high-performance liquid chromatography to be >98%, and its structure was fully verified with the measured molecular weight of 545 at M+1 peak corresponding to the FITC-MCT molecular weight of 544 through subsequent mass spectrometry (liquid chromatography/mass spectrometry, ZQ 2000; Waters). The compound structure was further confirmed by NMR analysis (Ascend 300; Bruker) showing the proton spectrum to be completely consistent with the FITC-MCT chemical formula of C 29 O 7 N 2 SH 24 .
Purification of CaSR Extracellular Domain
The gene encoding the rat CaSR extracellular domain (ECD, 1-612 amino acids) was synthesized and subcloned into pcDNA3.1(+) (Invitrogen) through Hind III and Not I with a tag insert of 10 histidine at the C-terminus. The correct subcloning and inserts were verified by sequencing in both forward and reverse directions using primers specific to the vector on an ABI 3730 Automated Sequencer (Applied Biosystems). The pcDNA3.1(+) CaSR ECD was transfected into HEK293T cells using 10 lg plasmid DNA and 30 lL Lipofectamine 2000 (Invitrogen) at the cell density of 10 6 cells/mL. The tranfsected HEK293T cells were cultured with Opti-MEM (Invitrogen), and the expression of exogenous protein was monitored every 24 hours for identifying the optimal time point to harvest. The recombinant CaSR ECD was obtained from the lysate of HEK293T cells through affinity purification using a standard Ni column (HisTrap Excel 1-mL Ni column; GE Healthcare) as follows. The Ni column was prebalanced with binding buffer containing 0.02 mol/L Na 2 HPO 4 /NaH 2 PO 4 (pH 7.4) and 0.5 mol/L NaCl at 2 mL/ min. The cell lysates were centrifuged at 2292 g for 10 minutes at 4°C. The aspirated supernatant was passed through a membrane filter with a diameter of 0.22 lm and then applied to the Ni column through an AKTA Prime fastperformance liquid chromatography system (GE Healthcare). The Ni column was completely rinsed with washing buffer containing 0.02 mol/L Na 2 HPO 4 /NaH 2 PO 4 (pH 7.4), 0.5 mol/L NaCl, and 30 mmol/L imidazole to eliminate bulk impurities. The CaSR ECD sample was then rinsed from the Ni column with elution buffer containing 0.02 mol/L Na 2 HPO 4 / NaH 2 PO 4 (pH 7.4), 0.5 mol/L NaCl, and 500 mmol/L imidazole and finally collected in PBS (pH 7.4) through ultrafiltration. The recombinant CaSR ECD was quantified with Pierce BCA Protein Assay Kit (Thermo Scientific), and the molecular size was verified by immunoblotting.
WaterLOGSY and Saturation Transfer Difference NMR
For WaterLOGSY (water ligand-observed gradient spectroscopy), the recombinant CaSR ECD and monocrotaline were dissolved at a final concentration of 5 lmol/L and 1 mmol/L, respectively, in 10 mmol/L PBS (pH 7.5) containing 10% D 2 O and then scanned on an NMR system (Ascend 850; Bruker) to obtain the proton spectrum for CaSR ECD and monocrotaline. Monocrotaline was subsequently added into the CaSR ECD solution at a series of final concentrations of 1, 2, 3, and 5 mmol/L, and the samples were subsequently scanned on the NMR at the saturation of water to obtain the WaterLOGSY spectrum. For saturation transfer difference, the recombinant CaSR ECD and monocrotaline were dissolved at a final concentration of 5 lmol/L and 1 mmol/L, respectively, in 10 mmol/L Tris, pD7.8 D 2 O, and then scanned on an NMR system (Ascend 700; Bruker) to obtain the proton spectrum for CaSR ECD and monocrotaline. The recombinant CaSR ECD was dissolved at a final concentration of 5 lmol/L in 10 mmol/L Tris, pD7.8 D 2 O, supplied with 1 mmol/L monocrotaline, then irradiated on the NMR system for 3 seconds at 2.0 and 30 ppm for the saturation and nonsaturation, respectively, of CaSR ECD.
Cell Culture
PAECs were cultured from the third-order branches of rat intralobar artery explants. The primary PAECs migrated from the artery explants with their intimal surface adhered to the culture dish were digested by trypsin, split, and maintained in DMEM supplemented with 5% fetus bovine serum. PAECs displayed the characteristic cobble stone-like morphology, and their purity was >95%, as identified by immunocytochemical staining with von Willebrand factor. The PAECs at %70% confluence in 1 to 3 passages were used in experiments. PAECs were isolated from at least 3 rats for each kind of experiment. 
Cytosolic

Transfection of short hairpin RNA
The effective short hairpin RNA (shRNA) specifically against CaSR, nonspecific control, and vector (Origene) were transfected into PAECs using Lipofectamine 2000, as described previously. 8, 18 The shRNA constructs simultaneously encoded DsRed for identification of transfected PAECs individually. 19 The transduction of shRNA for CaSR knockdown in vivo was conducted as we reported previously. 8 Briefly, the oligo-DNA encoding the control and the effective shRNA targeting CaSR were subcloned, respectively, into the Lenti-X shRNA expression vector (Clontech), confirmed by sequencing, and packaged into lentiviral particles using Lenti-X HTX packaging system and HEK293T cells (Clontech Figure S1 ).
Western Blot and Immunocytochemical Staining
To determine the thermal stability of CaSR prepared from pulmonary arteries of rats, the protein lysates were preheated at a series of temperatures from 42 to 72°C for 3 minutes and then subjected to Western blot, as described previously in detail.
To determine the binding of monocrotaline to CaSR in cultured PAECs, immunocytochemical staining was performed, as reported previously. 8, 18, 20 
CaSR Knockout
The CaSR and PTH double-knockout rats were created using a recently modified CRISPR/Cas9 technique.
22,23
The rat Casr gene (rCasr; GenBank accession number: NM_016996.1; Ensembl: ENSRNOG00000002265) is located on rat chromosome 11. Seven exons have been identified in rCasr, with the ATG start codon in exon 2 and TAA stop codon in exon 7. Exon 3 of the rCasr gene was selected as the Cas9 targeting region based on its critical importance in CaSR function, [24] [25] [26] and the targeting site was GTGGTGGGAGC-CACCGGCTC. The single guide RNA (gRNA) was constructed at a CRISPR/Cas9 expression vector, pRP[CRISPR]-hCas9_D10A-U6 (Cyagen Biosciences, Guangzhou, China), with a U6 promoter that can be in vitro transcribed into Cas9 mRNA and gRNA. As shown in Figure S2 , the pRP[CRISPR]-hCas9_D10A-U6 vector was constructed following the wellknown advancements in CRISPR/Cas9 technology. [27] [28] [29] The CRISPR/Cas9 expression plasmid was linearized and used as the template for in vitro transcription. The transcribed Cas9 mRNA and gRNA were both purified, and the mixture of Cas9 mRNA and gRNA was then injected into zygotes for SpragueDawley rat production. The founder animals (F0) were genotyped by tail biopsy followed by polymerase chain reaction using the forward primer Figure S3 . Two CaSR-heterozygous and 4 PTH-heterozygous rats were selected from the F0 rats to breed; the genotypes of the F0 heterozygous rats are displayed in Figure S4A . The rat heterozygous for missing 7 bases (CTCCGGT) in 1 strand of rCasr (F0_21#) and the one heterozygous for missing 2 bases (GC) in 1 strand of rPth (F0_26#) were fertile and bred to successfully generate offspring heterozygous rats at both the Casr and Pth loci (CaSR +/À PTH +/À F1_4# and 6#) ( Figure S4B ). The 2 latter were then used to generate
, and CaSR Figure S4C ). The genomewide off-target sites or candidates were screened using CRISPR Design (http://crispr. mit.edu), and none site was scored as possible off-target candidates for CaSR or PTH gRNA, respectively. Even so, 2 and 3 sites on the top score list of CaSR and PTH, respectively, were sequenced to verify no off-target activity.
The following primers were used for polymerase chain reaction: CaSR off-target site 1, chr10:+108706769: forward primer 5 0 -CCGCTAGGATTCGTTCCACGTC-3 0 , reverse primer 
Pulmonary Hypertension Model and Hemodynamic Measurements
Sprague-Dawley rats (male, 180-200 g, aged 4 weeks) received 1 subcutaneous administration of monocrotaline at 60 mg/kg, the standard dosage in rodent to produce the pulmonary hypertension model. 3, 4, 6, 9, [30] [31] [32] [33] [34] [35] [36] For treatment with CaSR inhibitor, rats received 10 days of intraperitoneal injection of Calhex 231 successively from day 1 at the dosage of 41 lg/kg each day, a protocol that was used successfully in a recent study to evaluate a CaSR inhibitor of pulmonary hypertension in rats. 9 Two weeks after the administration of monocrotaline, when stable pulmonary hypertension was established in rats, as documented previously, 9, 31, 33, 34, 36, 37 pulmonary hemodynamic studies were conducted, as described previously. 8 Animal experiments were performed in the following 14 groups. Group 1 received 1 subcutaneous administration of solvent (ethanol and PBS at 1:4) for monocrotaline at day 1 of the experiment (n=9). Group 2 received 1 subcutaneous administration of monocrotaline at 60 mg/kg at day 1 of experiment (n=10). Group 3 received 10 days of intraperitoneal injection of Calhex 231 successively from day 1 at a daily dosage of 41 lg/kg (n=8). Group 4 received 1 subcutaneous administration of monocrotaline at 60 mg/kg at the day 1 of experiment and 10 days of intraperitoneal injection of Calhex 231 successively from day 1 at the daily dosage of 41 lg/kg (n=8). Group 5 received an intravenous injection of 1 mL lentivirus (%10 8 TU/mL) packed with an empty shRNA vector for systemic CaSR knockdown 3 days before receiving 1 subcutaneous administration of monocrotaline on day 1 of the experiments (n=8). By the end of hemodynamic experiments, prewarmed saline was introduced into pulmonary circulation through the pulmonary artery catheter and drained from the left atrium to wash out the blood. The lungs and heart tissues were removed, and the lungs were fixed with formaldehyde solution (10%) for ≥3 days at room temperature. Right ventricular hypertrophy was quantified by weighing the right ventricular free wall and the left ventricle together with the septum (left ventricle plus septum). For the analysis of pulmonary morphometry, 1 sagittal 5-lm-thick section from the top, middle, and bottom of each left lung was embedded with paraffin. Two slides from each section were subjected to hematoxylin and eosin staining and examined at room temperature under an Olympus BX60 microscope using the Olympus UPlanFL 409/0.75 lens. Medial wall thickness was determined in distal pulmonary arteries with diameters between 50 and 150 lm, and image capture was performed using the Olympus DP50 camera with the aid of ViewFinder Lite software (Olympus).
Statistical Analysis
Data are reported as meanAESE. The Student's t test and 1-way ANOVA followed by Student-Newman-Keuls were used for 2-or multiple-group comparisons. Four-parameter logistic regression was performed for nonlinear regression. P<0.05 was considered significantly different.
Results
Monocrotaline Binds to CaSR
To Figure 2A , 5 lmol/L CaSR ECD and 1 mmol/L monocrotaline exhibited a distinct proton spectrum with weak signals in 10 mmol/L PBS containing 10% D 2 O on NMR (marked "a 1 " and "a 2 ," respectively). The concomitant presence of CaSR ECD and monocrotaline resulted in enormous enhancement of proton signals in several down fields of the monocrotaline spectrum, at 1.1, 1.3, 1.4, 2.2, 3.0, 3.6, 3 .8, and 6.2 ppm on NMR (marked "a 3 " in Figure 2A) , and the enhancement effect was dose-dependent on monocrotaline (marked "a 4 " through "a 7 " in Figure 2A) , strongly suggesting the possible binding of monocrotaline to CaSR ECD. Furthermore, we carried out saturation transfer difference NMR analysis with the purified 
mmol/L Tris in D 2 O on NMR (marked "b 1 " and "b 2 ," respectively). When CaSR-ECD was irradiated in the presence of 1 mmol/L monocrotaline on NMR for 3 seconds at 2.0 and 30 ppm for saturation and nonsaturation, respectively, of CaSR-ECD, the resulting saturation transfer difference (STD) clearly identified several increased proton signals at the down fields around 0.7, 0.9, 1.0, 1.7, 2.5, 3.0, and 6.5 ppm (marked "b 3 " in Figure 2B ), which completely coincided with the corresponding down fields of monocrotaline proton spectrum (marked "b 2 " in Figure 2B ) and thus confirmed the binding of monocrotaline to CaSR ECD. It is noted that N,N-dimethylformamide, the solvent of monocrotaline pyrrole (MCTP) prevented us from comparing any potentially enhanced or altered binding capacity of MCTP to CaSR versus monocrotaline, since N,N-dimethylformamide usually induces denaturalization of purified protein in vitro. In addition, N,N-dimethylformamide contains the intrastructures of methyl groups, which most likely interfere with the proton NMR spectrum by giving rise to 2 singlets of 3 protons by itself 38 and thus is treated as an inappropriate component in the sample preparations for NMR monitoring, even at a trace amount.
To examine whether monocrotaline was capable of ligating the native CaSR, we performed immunocytochemical staining of cultured PAECs. For this purpose, we labeled monocrotaline with FITC and then incubated FITC-MCT with PAECs with or without coimmunostaining of CaSR. As shown in Figure 3 , FITC-MCT incubation clearly showed localization of monocrotaline on the cell membrane and, to some extent, in the cytosol of PAECs (shown in green in Figure 3A and 3C, left), not in FITC-incubated control PAECs, ensuring the specificity of this staining ( Figure 3B, left) . Also shown in Figure 3 , indirect immunostaining showed the localization of CaSR on the cell membrane and, to some extent, in the cytosol of PAECs (shown in red in Figure 3A and 3B, middle). The expression of CaSR on the cell membrane and in the cytosol of PAECs was completely consistent with previous reports on other types of vascular endothelial cells including human aortic endothelial cells. 39 The coimmunostaining of CaSR in FITC-MCT-incubated PAECs further showed the yellow fluorescence resulting from the merging of the green fluorescence of monocrotaline and the red fluorescence of CaSR, indicating colocalization of monocrotaline together CaSR on the cell membrane and, to a lesser extent, in the cytosol of PAECs ( Figure 3A , right). It is noted that the structure of monocrotaline pyrrole (MCTP) and its relatively unstable property prevented us from labeling it with FITC or other types of fluorescent tracer. Considering the conversion of monocrotaline to MCTP in the liver after their injection into animals and the subsequent targeting of MCTP on PAECs, 5-7 the potential binding of MCTP to CaSR was explored in monocrotaline-injected rats as follows. To finally verify whether MCTP was able to combine with native CaSR in vivo, we conducted the cellular thermal shift assay on pulmonary arteries isolated from monocrotalineinjected rats. The cellular thermal shift assay is a recently established approach to reveal whether a chemical compound or drug can bind to a protein. 40, 41 The new technique methodologically exploits the chemical property of enhanced thermal stability of a protein on specific binding of a compound. 40, 41 The protein lysates of pulmonary arteries isolated from rats administered control (the vehicle DMSO), the chemical inhibitor of CaSR ([1S,2S,1
, or monocrotaline were heated at a series of temperatures from 42 to 72°C for 3 minutes and then subjected to immunoblotting analysis. In control-or DMSOtreated animals, the CaSR was stable below or at 48°C, was slightly degraded from 51 to 54°C, was significantly degraded at 57°C, and was almost completely degraded at 60°C ( Figure 3D ). In Calhex 231-treated animals, the CaSR was stable below or at 57°C, was slightly or significantly degraded from 60 to 63°C, and was almost completely degraded at 69 to 72°C ( Figure 3D ). In monocrotalinetreated animals, the CaSR was stable below or at 63°C, was slightly or significantly degraded from 66 to 69°C, and was not completely degraded even at 72°C ( Figure 3D ). As summarized in Figure 3E , the statistical regression analysis showed the significant right shift of thermal stability curves of CaSR in pulmonary arteries from animals administered monocrotaline or Calhex 231 compared with control or vehicle, clearly indicating the specific binding of MCTP to CaSR in vivo. These results consistently demonstrated the binding of monocrotaline or MCTP to CaSR.
Monocrotaline Induces the Activation of CaSR
To examine whether the binding of monocrotaline affected the functional status of CaSR, we evaluated the mobilization of intracellular calcium signaling ([Ca 2+ ] i ), one of the major downstream events after CaSR activation. 42 As shown in Figure 4A through 4H, the exposure of PAECs to 2.5 mmol/L monocrotaline, equivalent to the standard dosage used for the establishment of pulmonary hypertension in rats was completely abolished, further confirming the activation of CaSR by monocrotaline.
CaSR Mediates Monocrotaline-Induced Endothelial Injury
To reveal whether the activation of CaSR by monocrotaline functionally and eventually affected the integrity of PAECs, cell survival and cleaved caspase 3 were evaluated on exposure of monocrotaline in the presence or absence of the manipulation of CaSR function or expression. As shown in Figure 4I and 4J, the exposure of monocrotaline induced significant loss of cell survival and elevated levels of cleaved caspase 3, and both Calhex 231 and the knockdown of CaSR obviously inhibited monocrotaline-induced cell damage, respectively, suggesting that CaSR mediated monocrotaline-induced endothelial injury.
Monocrotaline Induces CaSR Assembly
To reveal the mechanism underlying how monocrotaline activated CaSR, we performed FRET analysis to determine the status of CaSR assembly, a sufficient step for CaSR activation. For this purpose, we simultaneously expressed CFP-CaSR and YFP-CaSR fused protein into cultured PAECs and then exposed the cells to 2.5 mmol/L monocrotaline. As shown in Figure 5 , the fluorescence transfer from CFP-CaSR to YFPCaSR was significantly enhanced on exposure of monocrotaline ( Figure 5A through 5C ), indicating the assembly of CaSR. To confirm these results, we conducted Western blots and identified the expression of CaSR with high molecular weight in PAECs after monocrotaline exposure ( Figure 5D ).
CaSR Mediates Monocrotaline-Induced Pulmonary Hypertension
To understand whether CaSR mediated monocrotalineinduced pulmonary hypertension, we evaluated the hemodynamics of pulmonary circulation and vascular remodeling in animals with or without inhibition of CaSR function, knockdown, or knockout of its expression. We started by evaluating the role of CaSR in monocrotalineinduced pulmonary hypertension, using the chemical inhibitor of CaSR Calhex 231, the potent negative allosteric modulator of CaSR. As shown in Figure 6 , the administration of Calhex 231 significantly attenuated monocrotaline-altered hemodynamic status of pulmonary circulation as well as the structure of pulmonaryarteries and right ventricle interms ofpulmonary artery pressure, pulmonary vascular resistance, vascular wall thickness, and Fulton's index, the index of right ventricular hypertrophy.
To further and more specifically reveal the role of CaSR in monocrotaline-induced pulmonary hypertension, we downmanipulated the expression of CaSR in rats using a series of strategies. We generated a global knockdown CaSR rat preparation by the intravenous injections of lentivirus-packed shRNA against CaSR, as we established previously 8 ( Figure S1 ).
As summarized in Figure 7A through 7E, CaSR knockdown at global level obviously attenuated monocrotaline-increased pulmonary artery pressure, pulmonary vascular resistance, vascular wall thickness, and right ventricular hypertrophy. To further confirm these findings, we prepared lungspecific knockdown rats by the intratracheal instillations of lentivirus-packed shRNA against CaSR, and our Western blots confirmed the tissue-specific knockdown of CaSR in the lungs, not in other major organs (heart, brain, liver, or kidney) as also downregulated in global knockdown rats ( Figure S1A through S1E). The lung CaSR knockdown rats did not show any abnormal serum phosphate, calcium, or PTH levels, as significantly noted in global knockdown preparations (Figure S1F through S1H) . Consistent with the findings with global knockdown rats, lung-specific knockdown of CaSR also attenuated monocrotaline-increased pulmonary artery pressure, pulmonary vascular resistance, vascular wall thickness, and right ventricular hypertrophy ( Figure 7F through 7J) .
To completely or fully verify the targeting role of CaSR, we constructed and bred CaSR knockout rats in this study ( Figures  S2 through S4) . CaSR À/À knockout rats died from severe hypercalcemia after birth; therefore, we developed PTH and CaSR double-knockout (PTH À/À /CaSR À/À ) animals, the general strategy for experimental studies with CaSR À/À knockout mice preparations. 43 As shown in Figure 8 , monocrotalineinduced elevations of pulmonary artery pressure, pulmonary vascular resistance, vascular wall thickness, and right ventricular hypertrophy were almost completely diminished in CaSR knockout (PTH
) rats, not in wild-type or control rats (PTH À/À ). Of note, the findings about monocrotalineinduced development of pulmonary hypertension in PTH À/À animals in this experimental study are in agreement with a previous investigation in patients showing that the development of pulmonary hypertension was not related to the level of PTH. 44 Our studies with a monocrotaline-administered rat model showed significantly attenuated or almost completely abolished pulmonary hypertension by the inhibitor of CaSR, global or lung tissue knockdown or knockout of CaSR, thus finally and strongly demonstrating the role of CaSR as the target underlying monocrotaline-induced pulmonary hypertension.
Discussion
The structural basis for monocrotaline-targeting protein may be associated with the amino acids of cysteine, histidine, and tryptophan, as suggested in earlier studies, 11, 14 and a specific motif of Cys-Xaa-Xaa-Cys (CXXC), as revealed in recent studies. 12, 13 CaSR contains 4 CXXC motifs and 1 CXXXC motif. 45 The extracellular domain of CaSR houses 3 of the 4 CXXC motifs and the CXXXC motif as well as 19 cysteines, 13 histidines, and 10 tryptophans (3.2%, 2.2%, and 1.7%, respectively, of total amino acids of ECD). These structures can provide a possible explanation for the binding of monocrotaline to CaSR. Although no one molecule has been identified as the molecular target for monocrotaline-induced pulmonary hypertension, amino acid comparison between CaSR and several known candidates claimed previously for the development of pulmonary hypertension interestingly reveals the superior structure of CaSR in housing more cysteines, histidines, and tryptophans as well as CXXC motifs over the other molecules such as metabotropic glutamate receptor 5, TRPC1, TRPC4, TRPC6, TRPV4; the KCNE1, KCNA5, KCNMB2, KCNMB3, and KCNJ5 potassium channels; endothelin 1, endothelin A receptor, endothelin B receptor, angiotensin II receptor 1, 5-HT receptor 2A, endothelial and inducible nitric oxide synthases, bone morphogenetic protein receptor type II, matrix metalloproteinase-2, hypoxia-inducible factor-1a, Nuclear factor of activated T-cells (cytoplasmic 3), hypoxia-induced mitogenic factor, RhoA, protein-disulfide isomerase, and tropomyosin 1. CaSR was not listed among the molecules with potential binding to monocrotaline in a previous study by Lam e et al. 13 The failure of the study to identify CaSR as a monocrotaline-binding protein may be due to its high molecular weight. The proteins with high molecular weight could have been missed by techniques such as sample soaking and gel composition, as also stated in the study. The dosage of monocrotaline used in vitro in the current study was adopted from well-established investigations previously conducted to reveal the binding 12, 13 and cellular toxicity of monocrotaline. [46] [47] [48] The dosage was also in the range of estimated or calculated serum concentration of monocrotaline after its administration into rats by the standard protocol at 60 mg/kg body weight in inducing pulmonary hypertension. 3, 4, 6, 9, [30] [31] [32] [33] [34] [35] [36] Both monocrotaline and MCTP were used in previous studies with isolated blood cells or cultured PAECs in vitro. 12, 13, 49 In the pilot experiments with
CaSR protein preparations, we prepared MCTP and tried to use MCTP instead of monocrotaline, as Segall and colleagues did previously. 12, 13 We found, however, that MCTP aggregated in water to form red insoluble polymers, as reported previously, 50, 51 and this prevented us from exploring its binding to CaSR by proton NMR spectroscopy or labeling it with FITC. This might have been the reason for the use of monocrotaline instead of MCTP in experiments using proton NMR spectroscopy in a previous study. 49 Of note, our conclusion about the binding of monocrotaline to CaSR in protein preparation and in cultured PAECs was further supported by our cellular thermal shift assay experiments aiming to confirm the binding of MCTP to CaSR in vivo using the pulmonary arteries isolated from monocrotaline-administered rats, under which MCTP was generally believed to be the major form of monocrotaline metabolites targeting pulmonary endothelial cells. To the best of our knowledge, the binding of MCTP to any molecule in vivo has not been evaluated in any previous studies.
Monocrotaline can bind to other proteins in addition to CaSR, as stated in previous studies. 12, 13 This study, therefore, aimed to reveal the potential role of CaSR in mediating the development of pulmonary hypertension by a serious analysis of phenotype. Our physiological results using 3 different preparations of CaSR-manipulated animals strongly indicated the functional role of CaSR after being bound and altered by monocrotaline. In other words, monocrotaline may bind to proteins, not merely to CaSR; however, CaSR is the first one, to the best of our knowledge, that monocrotaline can not only bind to but also cause the activation or alteration of its functional status. The activation of CaSR by the binding of monocrotaline seemed to result from the assembly of CaSR ( Figure 5 ), and the monocrotaline-induced CaSR assembly may in turn result from the aggregation of monocrotaline itself, thus providing multiple binding sites. 52 The signaling pathways involved in monocrotaline-induced endothelial injury and pulmonary hypertension that are well known and well studied include Smad, TGF-b/Alk5, and Rho. 35, 36, 53, 54 These pathways also appear to be or associated with the downstream events on activation of CaSR, 42, 55, 56 providing an additional line of support for the role of CaSR in mediating the effect of monocrotaline. Nevertheless, this study does not exclude the possible co-contributions of other proteins bound and functionally altered by monocrotaline, particularly those signaling molecules cross-talking with the downstream pathways on CaSR activation. A recent study showed that the CaSR inhibitor NPS 2143 attenuated the development of monocrotaline-induced pulmonary hypertension by decreasing upregulated expression in CaSR. 9 Our findings on inhibition of monocrotaline-induced pulmonary hypertension by the CaSR inhibitor Calhex 231 in the current study are completely consistent with that report. A possible explanation is that the CaSR inhibitor may be able to diffuse into the cell from its well-known binding sites in the transmembrane domain of CaSR. 57 Specifically, the binding of CaSR inhibitors to CaSR precursors could interfere with their posttranslational modification, maturation, and/or membrane translocation. In support of this possibility, our cytoimmunochemical stainings demonstrated the localization of CaSR, presumably the pre-matured form of CaSR in the cytosol of PAEC (Figure 3) , as reported previously in other types of vascular endothelial cells. 38 The activation of CaSR has been well established to stimulate or enhance transcriptional activity of nuclear factor jB 58 and Sp1, 59 the transcriptional regulators harbored in the promoters of the CaSR gene. 60 Indeed, activators of CaSR such as extracellular calcium 42 have been shown to upregulate the transcription and gene or protein expression of CaSR. 42, 60 Thus, the activation of CaSR seems to upregulate the expression of CaSR in a positive-feedback manner. The findings of the current study on the binding of monocrotaline to CaSR and the subsequent activation of CaSR, together with its wellknown downstream signaling cascades, may provide an alternative explanation for the upregulated CaSR expression in monocrotaline-administered animals 9 and CaSR inhibitorattenuated development of monocrotaline-induced pulmonary hypertension, as reported in the previous study 9 and the current one.
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